Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients
Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients Prostate Cancer and Prostatic Diseases advance online publication, December 24 2013. doi:10.1038/pcan.2013.56 Authors: T Kamigaito, T Okaneya, M Kawakubo, H Shimojo, O Nishizawa &J Nakayama
Conditions: Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Drug: Abiraterone Acetate; Drug: Antiandrogen Therapy; Drug: Apalutamide; Drug: Prednisone; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: OHSU Knight Canc...
ConclusionThis case report describes a brain metastasis of a rare aggressive type of prostate cancer with poor prognosis. With metastatic lesions of prostatic adenocarcinoma, the probability of NE transdifferentiation increases. LCNEC has a poor prognosis attributed to its nature and late diagnosis. Thus, reporting and investigating such tumor will positively contribute to better management for future patients
We report a case of an 83-year-old man with castration-resistant prostate cancer in whom a metastasis to the thyroid cartilage was the only site of relapse.
We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up 99mTc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Our case report raises the association between prostate cancer patients treated with externa...
68Ga-PSMA PET/CT imaging is an emerging imaging modality in prostate cancer. PSMA expression is also reported for nonprostate malignancies, including primary hepatocellular carcinoma. Herein, we present a case of a 74-year-ald man with recently diagnosed hepatocellular carcinoma who was referred for 18F-FDG PET/CT imaging for initial staging. The patient underwent 18F-FDG PET/CT as part of staging procedure; he also underwent 68Ga-PSMA PET/CT. PET/CT images revealed only slight 18F-FDG uptake in the liver lesion, but intense 68Ga-PSMA uptake, without any metastatic lesion seen elsewhere in the body.
Publication date: Available online 5 February 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Ana Margarida Abrantes, Ana Salomé Pires, Lúcia Monteiro, Ricardo Teixo, Ana Rita Neves, Nuno Tiago Tavares, Inês Alexandra Marques, Maria Filomena BotelhoAbstractCarcinogenesis is a complex multistep process, characterized by changes at different levels, both genetic and epigenetic, which alter cell metabolism. Positron emission tomography (PET) is a very sensitive image modality that allows to evaluate oncometabolism. PET functionalities are immense, since by labelling a...
Conditions: Metastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Behavioral: Questionnaire; Procedure: Biospecimen Collection; Diagnostic Test: Genetic Testing; Other: Genetic Counseling; Other: Laboratory Biomarker Analysis Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI) Enrolling by invitation